Lantheus/$LNTH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lantheus
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
- Ticker
- $LNTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,193
- Headquarters
- Bedford, United States
- Website
- www.lantheus.com
Lantheus Metrics
BasicAdvanced
$6.5B
24.12
$4.15
-0.03
-
Price and volume
Market cap
$6.5B
Beta
-0.03
52-week high
$111.86
52-week low
$50.16
Average daily volume
952K
Financial strength
Current ratio
3.06
Quick ratio
2.822
Long term debt to equity
0.476
Total debt to equity
0.435
Interest coverage (TTM)
15.33%
Profitability
EBITDA (TTM)
392.225
Gross margin (TTM)
60.14%
Net profit margin (TTM)
17.69%
Operating margin (TTM)
19.52%
Effective tax rate (TTM)
24.15%
Revenue per employee (TTM)
$1,300,000
Management effectiveness
Return on assets (TTM)
8.38%
Return on equity (TTM)
22.21%
Valuation
Price to earnings (TTM)
24.118
Price to revenue (TTM)
4.226
Price to book
4.98
Price to tangible book (TTM)
17.05
Price to free cash flow (TTM)
16.958
Free cash flow yield (TTM)
5.90%
Free cash flow per share (TTM)
5.906
Growth
Revenue change (TTM)
2.35%
Earnings per share change (TTM)
10.07%
3-year revenue growth (CAGR)
11.43%
10-year revenue growth (CAGR)
17.90%
3-year earnings per share growth (CAGR)
104.89%
10-year earnings per share growth (CAGR)
16.68%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Analyst projections of the future price of Lantheus stock.
Bulls say / Bears say
The wider portfolio is cushioning pressure on the flagship product: Q2 revenue rose 2.7% to $388.2 million even as PYLARIFY declined, helped by growth in DEFINITY and other businesses. This gives Lantheus a broader earnings base than a pure single-product story. (Lantheus)
Lantheus secured FDA approval for PYLARIFY TruVu and tentative approval for PNT2003 in the first quarter. TruVu’s planned fourth-quarter launch and PNT2003’s potential to broaden the radiopharmaceutical portfolio provide identifiable catalysts beyond the existing franchise. (Lantheus)
The agreed Curium takeover offers $102.50 per share in cash at closing, plus contingent value rights worth up to $12.00 per share if commercial milestones are met. The combination also pairs Lantheus’ US commercial platform with Curium’s global manufacturing and theranostics capabilities. (Lantheus, Curium Pharma)
Core earnings momentum is softening: Q2 PYLARIFY sales fell 4.1%, while adjusted operating income and adjusted EPS declined 6.9% and 1.3%, respectively. Lantheus also suspended its 2026 guidance after agreeing the Curium transaction, reducing near-term visibility. (Lantheus)
The FDA issued a Complete Response Letter for LNTH-2501 because of unresolved manufacturing issues at a third-party facility. Although the regulator raised no clinical, safety or efficacy concerns, the setback delays a potential growth product and leaves the resubmission timetable uncertain. (Reuters)
PYLARIFY TruVu’s approval does not guarantee a smooth commercial launch. Lantheus still needs manufacturing-site approvals, favourable coding and reimbursement, and customer adoption before the planned phased launch can deliver its expected benefits. (Lantheus)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Lantheus News
AllArticlesVideos
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Business Wire4 weeks ago
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire1 month ago
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Reuters2 months ago
Funds containing Lantheus
AllUSDEURGBP
Fund name | Fund size | $LNTH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.68% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.68% |
iShares Healthcare Innovation£DRDR | £1B | 0.68% |
iShares Ageing Population€AGED | €822M | 0.50% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.22% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.